Lawrence A Kenyon - Net Worth and Insider Trading

Lawrence A Kenyon Net Worth

The estimated net worth of Lawrence A Kenyon is at least $7,729 dollars as of 2024-04-20. Lawrence A Kenyon is the CEO, Pres, CFO, Treas & Secy of Outlook Therapeutics Inc and owns about 946 shares of Outlook Therapeutics Inc (OTLK) stock worth over $7,729. Details can be seen in Lawrence A Kenyon's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Lawrence A Kenyon has not made any transactions after 2021-04-20 and currently still holds the listed stock(s).

Transaction Summary of Lawrence A Kenyon

To

Lawrence A Kenyon Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Lawrence A Kenyon owns 2 companies in total, including Outlook Therapeutics Inc (OTLK) , and Arno Therapeutics Inc (ARNI) .

Click here to see the complete history of Lawrence A Kenyon’s form 4 insider trades.

Insider Ownership Summary of Lawrence A Kenyon

Ticker Comapny Transaction Date Type of Owner
OTLK Outlook Therapeutics Inc 2021-04-20 CFO and Secretary
ARNI Arno Therapeutics Inc 2014-02-24 Chief Financial Officer

Lawrence A Kenyon Latest Holdings Summary

Lawrence A Kenyon currently owns a total of 1 stock. Lawrence A Kenyon owns 946 shares of Outlook Therapeutics Inc (OTLK) as of April 20, 2021, with a value of $7,729.

Latest Holdings of Lawrence A Kenyon

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
OTLK Outlook Therapeutics Inc 2021-04-20 946 8.17 7,729

Holding Weightings of Lawrence A Kenyon


Lawrence A Kenyon Form 4 Trading Tracker

According to the SEC Form 4 filings, Lawrence A Kenyon has made a total of 3 transactions in Outlook Therapeutics Inc (OTLK) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in Outlook Therapeutics Inc is the acquisition of 500 shares on April 20, 2021, which cost Lawrence A Kenyon around $18,300.

Insider Trading History of Lawrence A Kenyon

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Lawrence A Kenyon Trading Performance

GuruFocus tracks the stock performance after each of Lawrence A Kenyon's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Lawrence A Kenyon is -24.88%. GuruFocus also compares Lawrence A Kenyon's trading performance to market benchmark return within the same time period. The performance of stocks bought by Lawrence A Kenyon within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Lawrence A Kenyon's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Lawrence A Kenyon

Average Return

-42.34%

Average return per transaction

Outperforming Transactions

50%

1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 18.29 -24.88 -24.46 -42.34 -31.62 -40.89
Relative Return to S&P 500(%) 17.21 -30.45 -32.6 -57.75 -41.53 -53.2

Lawrence A Kenyon Ownership Network

Ownership Network List of Lawrence A Kenyon

No Data

Ownership Network Relation of Lawrence A Kenyon


Lawrence A Kenyon Owned Company Details

What does Outlook Therapeutics Inc do?

Who are the key executives at Outlook Therapeutics Inc?

Lawrence A Kenyon is the CFO and Secretary of Outlook Therapeutics Inc. Other key executives at Outlook Therapeutics Inc include Chief Commercial Officer Jeff Evanson , Chief Operating Officer Terry Dagnon , and director & CEO and President Trenary C Russell Iii .

Outlook Therapeutics Inc (OTLK) Insider Trades Summary

Over the past 18 months, Lawrence A Kenyon made no insider transaction in Outlook Therapeutics Inc (OTLK). Other recent insider transactions involving Outlook Therapeutics Inc (OTLK) include a net sale of 368,671 shares made by Jeff Evanson , a net sale of 520,000 shares made by Terry Dagnon , and a net purchase of 1,882 shares made by Yezan Munther Haddadin .

In summary, during the past 3 months, insiders sold 0 shares of Outlook Therapeutics Inc (OTLK) in total and bought 5,006 shares, with a net purchase of 5,006 shares. During the past 18 months, 47,558 shares of Outlook Therapeutics Inc (OTLK) were sold and 5,006 shares were bought by its insiders, resulting in a net sale of 42,552 shares.

Outlook Therapeutics Inc (OTLK)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Outlook Therapeutics Inc Insider Transactions

No Available Data

Lawrence A Kenyon Mailing Address

Above is the net worth, insider trading, and ownership report for Lawrence A Kenyon. You might contact Lawrence A Kenyon via mailing address: C/o Outlook Therapeutics, Inc., 7 Clarke Drive, Cranbury Nj 08512.

Discussions on Lawrence A Kenyon

No discussions yet.